FSE: SCH NYSE:
SHR
Indice: DAX
30
Schering AG is a research-based
pharmaceutical company. Its activities are focused on four business areas:
Gynecology&Andrology, Diagnostics&Radiopharmaceuticals, Dermatology
as well as Specialized Therapeutics for disabling diseases in the fields
of the central nervous system, oncology and cardiovascular system. As a
global player with innovative products Schering AG aims for leading positions
in specialized markets worldwide. With in-house R&D and supported by
an excellent global network of external partners, Schering AG is securing
a promising product pipeline. Using new ideas, Schering AG aims to make
a recognized contribution to medical progress and strives to improve the
quality of life: making medicine work
Schering est un des acteurs
majeurs de l'industrie pharmaceutique.
- contraception et traitement
hormonal : contraceptif par voie orale (Diane, Mycrogynon), produits
de traitement hormonal (patchs Climara, Mirena), traitement de la ménopause
(Climen), traitement de l'endométrite (Endometrion)
- médicaments
: traitement de la sclérose (Betaferon/Betaseron), de la leucémie
(Fludara), du cancer de la prostate (Androcur) et des problèmes
cardiovasculaires (Betapace)
- produits de diagnostic
: produits pour la radiologie classique (Iopamiron, Ultravist), pour l'IRM
(n°1 mondial ; Magnevist) et pour la radiologie par ultrasons (Levovist)
- dermatologie : traitement
des maladies de la peau (Nerisona), corticoïdes pour l'eczéma
(Advantan), produits contre l'acné (Skinoren)
Oral
formulation of Fludara® approved in Japan
Berlin
- Bayer Schering Pharma AG announced today that the oral formulation of
Fludara®
for low-grade non-Hodgkin’s Lymphoma and mantle cell lymphoma has received
marketing approval in Japan. This new formulation provides a new avenue
for simpler and easier outpatient chemotherapy to improve patients’ quality
of life, as well as that of their families. Bayer Schering Pharma plans
to start marketing of Fludara® Oral after National Healthcare Insurance
price listing.
"With
the approval of Fludara® Oral in Japan, we are right on track to further
expand our leadership position in hematological oncology," said Paolo Pucci,
Head of the Oncology Business Unit at Bayer Schering Pharma. "The addition
of Fludara® Oral to our portfolio will strengthen our position in Japan,
the world’s second largest pharmaceutical market."
Interim
Report Q1-3/2006
Q1-3/2006
at a Glance
NET
SALES GROWTH: +7%
OPERATING
PROFIT: +20% (adjusted)
BETAFERON®:
+16%
In
the first nine months of 2006, the Schering AG Group achieved an organic
net sales growth of 9%.
Negative
structure effects slightly impacted net sales growth. In total, net sales
increased by 7% to €4,180m in comparison to the previous year’s figures.
In the third quarter of 2006, total net sales remained at the previous
year’s level. After adjusting for structure and negative currency effects,
net sales increased by 5%. The recall of our X-ray contrast agent Ultravist®
in the formulation 370 mgI/ml
had
a negative impact on net sales. After adjusting for this effect, net sales
increased by 7% in the third quarter 2006.
The
operating profit during the first nine months of 2006 was €690m, 3%
below the previous year’s result. After adjusting for one-time effects
amounting to €163m in connection with divestitures and takeover-related
expenses, the operating profit increased by 20% to €853m. Including
these one-time effects, net profit (€466m) and earnings per share
(€2.45) were each 3% below the previous year’s level.
Cash
flows from operating activities amounted to €733m, 9% below the first
nine months of 2005. OnSeptember 30, 2006, the net cash position (net of
cash and cash equivalents, marketable securities and borrowings) was €1,311m
in comparison to €954m at the end of 2005.
Key
data €m Change €m Change
Q1-3/2006
Q1-3/2005 in % Q3/2006 Q3/2005 in %
Net
sales 4,180 3,902 +7% 1,356 1,355 0%
Gross
profit 3,219 2,972 +8% 1,044 1,036 +1%
Operating
profit 690 710 –3% 280 244 +15%
Profit
before taxes 734 751 –2% 291 248 +17%
Net
profit 466 480 –3% 165 160 +3%
Cash
flows from operating activities 733 805 –9% 199 385 –48%
Basic
earnings per share (€) 2.45 2.53 –3% 0.87 0.85 +2%
Employees
(Sept. 30, 2006 / Dec. 31, 2005) 23,050 24,124 –4% – – –
Top-selling
products Net sales Q1-3/2006 Change from Q1-3/2005
€m
total currency adjusted
1.
Betaferon®/Betaseron® (Specialized Therapeutics) 727 +16% +16%
2.
Yasmin®* (Gynecology&Andrology) 566 +34% +33%
3.
Magnevist® (Diagnostic Imaging) 240 0% 0%
4.
Mirena® (Gynecology&Andrology) 217 +28% +27%
5.
Ultravist® (Diagnostic Imaging) 174 –8% –10%
6.
Iopamiron® (Diagnostic Imaging) 160 –10% –5%
7.
Diane® (Gynecology&Andrology) 134 +3% 0%
8.
Microgynon® (Gynecology&Andrology) 110 +12% +10%
9.
Meliane® (Gynecology&Andrology) 93 0% –2%
10.
Fludara® (Oncology) 91 +16% +15%
Total
2,512 +13% +12%
Total
as % of Group sales 60%
*
Net sales include net sales of Yasmin®, YAZ® and Yasminelle®
In
this Interim Report, percentage changes in our depiction of sales developments
have been calculated on the basis of figures
expressed
in thousands of euros.
Schering
AG licenses SEGRA compound for ophthalmic use to Bausch & Lomb
Berlin,
Germany, and Rochester, New York, USA
Schering
AG, Germany (FSE: SCH; NYSE: SHR) and Bausch & Lomb (NYSE: BOL) announced
today that Schering has granted an exclusive worldwide license to Bausch
& Lomb to develop and market a selective glucocorticoid receptor agonist
(SEGRA) for the non-systemic treatment of eye disorders.
Bausch
& Lomb will evaluate the compound’s potential as a novel anti-inflammatory
medication with an improved safety profile in ophthalmological indications.
Today, glucocorticoids are the most potent and most frequently used anti-inflammatory
compounds, but their value is limited by side effects such as glaucoma
induction. SEGRAs, using a distinct molecular mechanism after binding to
a glucocorticoid receptor, may demonstrate a superior effect/side effect
profile when compared to standard glucocorticoids.
“The
collaboration with Bausch & Lomb is an excellent opportunity for us
to broadly explore the potential of SEGRAs and capitalize on the full value
of these compounds,” said Dr. Khusru Asadullah, Head of Inflammation Research
at Schering AG. |
